NEW YORK (GenomeWeb) – Rosetta Genomics today announced New York State has given final approval for the RosettaGx Reveal thyroid cancer test.
The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases. Rosetta’s laboratory is CLIA-certified but it required additional licensure from New York in order to receive and process samples for the test from residents in the state.
On Tuesday, the company announced it was realigning its strategy to redirect most of its sales and marketing sources to promote the Reveal test. In preliminary first quarter results, Reveal sales rose 54 percent quarter over quarter.